Episode Details

Bristol-Myers Squibbs stock has surged, but a closer look reveals a less rosy picture. Despite a strong first quarter, the companys revenue growth has been sluggish over the past five years, and analysts predict a four percent revenue drop in the next twelve months. Earnings per share have also been declining, and the companys valuation, while fair, may not justify the risk given the mixed signals. Investors might consider other opportunities in tech or software giants instead.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/abf8d07490049b06